中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 38 Issue 7
Jul.  2022
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2022  >  38(7): 1477-1481

HBeAg-negative chronic HBV-infected individuals with normal alanine aminotransferase and an age of ≤30 years should be taken seriously when expanding anti-HBV treatment for chronic hepatitis B

DOI: 10.3969/j.issn.1001-5256.2022.07.006
  • 1.

    Department of Microbiology and Infectious Disease Center, School of Basic Medical Sciences, Peking University, Beijing 100191, China

  • 2.

    Department of Epidemiology and Biostatistics, College of Public Health, Zhengzhou University, Zhengzhou 450001, China

  • 3.

    Department of Infectious Diseases, Peking University First Hospital, Beijing 100034, China

  • 4.

    Department of Infectious Diseases, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China

  • 5.

    Department of Pathology and Hepatology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing 100039, China

  • 6.

    Peking University Hepatology Institute, Peking University People's Hospital, Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases, Beijing 100044, China

Research funding:

The National S & T Major Project for Infectious Diseases (2017ZX10302201)

More Information
  • Corresponding author: ZHAO Jingmin, jmzhao302@163.com(ORCID: 0000-0003-4345-2149); LU Fengmin, lu.fengmin@hsc.pku.edu.cn(ORCID: 0000-0002-1832-3209)
  • Received Date: 2022-04-14
  • Accepted Date: 2022-05-24
  • Published Date: 2022-07-20
    Abstract
  •   Objective  To validate and refine the recommendations in the recently published expert opinion on expanding anti-HBV treatment for chronic hepatitis B.  Methods  Adult individuals with chronic HBV infection and normal alanine aminotransferase (ALT) who underwent liver biopsy in The Fifth Medical Center of Chinese PLA General Hospital from January 2014 to October 2020 were enrolled in this single-center retrospective study, and the proportion of individuals with moderate or severe liver injury was analyzed in the population with different HBeAg status in the ≤30 years and > 30 years subgroups.  Results  A total of 290 individuals with chronic HBV infection were included, among whom 121 (41.7%) were HBeAg positive and 169 (58.3%) were HBeAg negative. The HBeAg-positive group and the HBeAg-negative group were further divided into subgroups according to age: in the HBeAg-positive group, 37 were aged ≤30 years and 84 were aged > 30 years; in the HBeAg-negative group, 24 were aged ≤30 years and 145 were aged > 30 years. There were significant differences between the four groups in age (H=151.539, P < 0.05), sex (χ2=9.959, P < 0.05), ALT (H=29.041, P < 0.05), aspartate aminotransferase (H=11.127, P < 0.05), albumin (H=23.538, P < 0.05), HBV DNA (H=187.982, P < 0.05), and HBsAg (H=132.520, P < 0.05). In both > 30 years and ≤30 years groups, nearly 50% of the patients had a moderate or higher grade of liver injury (50.22% vs 47.54%). According to HBeAg status and age, the patients were further divided into HBeAg-positive ≤30 years group with 37 patients, HBeAg-positive > 30 years group with 84 patients, HBeAg-negative ≤30 years group with 24 patients, and HBeAg-negative > 30 years group with 145 patients. In the HBeAg-positive group, there was no significant difference in the proportion of patients with a moderate or higher grade of liver injury between the patients aged > 30 years and those aged ≤30 years (42.9% vs 37.8%, P=0.605), and there was also no significant difference in such proportion between the HBeAg-negative ≤30 years group and the HBeAg-negative/positive > 30 years groups (62.5% vs 54.5%, P=0.464). In the cohort for which a decision could not be made based on noninvasive indices (269 patients with liver stiffness measurement < 9.0 kPa or without the data of liver stiffness measurement but with fibrosis-4 < 3.25), there was no significant difference in the proportion of patients with a moderate or higher grade of liver injury between the HBeAg-negative ≤30 years group and the HBeAg-negative/positive > 30 years groups (59.1% vs 50.7% and 59.1% vs 41.8%, P=0.468 and 0.149).  Conclusion  HBeAg-negative chronic HBV-infected individuals with an age of ≤30 years should be taken into consideration when expanding anti-HBV treatment for chronic hepatitis B. If conditions permit, the revised flow chart for the initiation of anti-HBV treatment based on this study can be applied to further improve the precision of individualized anti-HBV treatment.

     

    • FullText(HTML)
  • loading
    • References(16)
  • [1]
    Chinese Society of Hepatology, Chinese Medical Association. Expert opinion on expanding anti-HBV treatment for chronic hepatitis B[J]. Chin J Hepatol, 2022, 30(2): 131-136. DOI: 10.3760/cma.j.cn501113-20220209-00060

    中华医学会肝病学分会. 扩大慢性乙型肝炎抗病毒治疗的专家意见[J]. 中华肝脏病杂志, 2022, 30(2): 131-136. DOI: 10.3760/cma.j.cn501113-20220209-00060
    [2]
    ZHUANG H. Should both patient's age and family history be necessary as the criteria for initiating treatment of HBeAg-positive or negative patients with chronic hepatitis B virus infection and normal alanine aminotransferase?[J]. Chin J Hepatol, 2022, 30(2): 230-232. DOI: 10.3760/cma.j.cn501113-20220129-00051.

    庄辉. ALT正常HBeAg阳性或阴性慢性乙型肝炎病毒感染患者治疗是否必须同时兼备年龄和家族史?[J]. 中华肝脏病杂志, 2022, 30(2): 230-232. DOI: 10.3760/cma.j.cn501113-20220129-00051.
    [3]
    European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection[J]. J Hepatol, 2017, 67(2): 370-398. DOI: 10.1016/j.jhep.2017.03.021.
    [4]
    Chinese Society of Infectious Diseases, Chinese Medical Association; Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B (version 2019)[J]. J Clin Hepatol, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.

    中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.
    [5]
    CUI FQ, BI SL, ZHANG Y, et al. Combination profiles of hepatitis B marks for Chinese in serosurvey in 2006[J]. Chin J Vaccines Immunization, 2009, 15(4): 294-299. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGJM200904005.htm

    崔富强, 毕胜利, 张勇, 等. 中国人群大样本调查乙型肝炎病毒感染血清学标志物检出模式分析[J]. 中国疫苗和免疫, 2009, 15(4): 294-299. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGJM200904005.htm
    [6]
    Chinese Society of Infectious and Parasitic Diseases, Chinese Medical Association; Chinese Society of Hepatology, Chinese Medical Association. Prevention and Control of Viral Hepatitis[J]. Chin J Intern Med, 2001, 40(1): 62-68. DOI: 10.3760/j.issn:0578-1426.2001.01.034.

    中华医学会传染病与寄生虫病学分会, 中华医学会肝病学分会. 病毒性肝炎防治方案[J]. 中华内科杂志, 2001, 40(1): 62-68. DOI: 10.3760/j.issn:0578-1426.2001.01.034.
    [7]
    Chinese Foundation for Hepatitis Prevention and Control; Chinese Society of Infectious Disease and Chinese Society of Hepatology, Chinese Medical Association; Liver Disease Committee of Chinese Research Hospital Association. Consensus on clinical application of transient elastography detecting liver fibrosis: a 2018 update[J]. Chin J Hepatol, 2019, 27(3): 182-191. DOI: 10.3760/cma.j.issn.1007-3418.2019.03.004.

    中国肝炎防治基金会, 中华医学会感染病学分会, 中华医学会肝病学分会和中国研究型医院学会肝病专业委员会. 瞬时弹性成像技术诊断肝纤维化专家共识(2018年更新版)[J]. 中华肝脏病杂志, 2019, 27(3): 182-191. DOI: 10.3760/cma.j.issn.1007-3418.2019.03.004.
    [8]
    KIM WR, BERG T, ASSELAH T, et al. Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients[J]. J Hepatol, 2016, 64(4): 773-780. DOI: 10.1016/j.jhep.2015.11.012.
    [9]
    GONG X, YANG J, TANG J, et al. A mechanistic assessment of the discordance between normal serum alanine aminotransferase levels and altered liver histology in chronic hepatitis B[J]. PLoS One, 2015, 10(7): e0134532. DOI: 10.1371/journal.pone.0134532.
    [10]
    YAN Y, ALLWEISS L, YANG D, et al. Down-regulation of cell membrane localized NTCP expression in proliferating hepatocytes prevents hepatitis B virus infection[J]. Emerg Microbes Infect, 2019, 8(1): 879-894. DOI: 10.1080/22221751.2019.1625728.
    [11]
    CHU CM, HUNG SJ, LIN J, et al. Natural history of hepatitis B e antigen to antibody seroconversion in patients with normal serum aminotransferase levels[J]. Am J Med, 2004, 116(12): 829-834. DOI: 10.1016/j.amjmed.2003.12.040.
    [12]
    MCMAHON BJ, HOLCK P, BULKOW L, et al. Serologic and clinical outcomes of 1536 Alaska Natives chronically infected with hepatitis B virus[J]. Ann Intern Med, 2001, 135(9): 759-768. DOI: 10.7326/0003-4819-135-9-200111060-00006.
    [13]
    HSU YS, CHIEN RN, YEH CT, et al. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B[J]. Hepatology, 2002, 35(6): 1522-1527. DOI: 10.1053/jhep.2002.33638.
    [14]
    CHU CM, LIAW YF. HBsAg seroclearance in asymptomatic carriers of high endemic areas: appreciably high rates during a long-term follow-up[J]. Hepatology, 2007, 45(5): 1187-1192. DOI: 10.1002/hep.21612.
    [15]
    CHEN JD, YANG HI, ILOEJE UH, et al. Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death[J]. Gastroenterology, 2010, 138(5): 1747-1754. DOI: 10.1053/j.gastro.2010.01.042.
    [16]
    NGUYEN MH, GARCIA RT, TRINH HN, et al. Histological disease in Asian-Americans with chronic hepatitis B, high hepatitis B virus DNA, and normal alanine aminotransferase levels[J]. Am J Gastroenterol, 2009, 104(9): 2206-2213. DOI: 10.1038/ajg.2009.248.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)  / Tables(2)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (668) PDF downloads(147) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return